Compare RMBI & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RMBI | RANI |
|---|---|---|
| Founded | 1887 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.3M | 120.0M |
| IPO Year | 2019 | 2021 |
| Metric | RMBI | RANI |
|---|---|---|
| Price | $14.32 | $1.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 11.4K | ★ 1.2M |
| Earning Date | 01-22-2026 | 11-06-2025 |
| Dividend Yield | ★ 4.18% | N/A |
| EPS Growth | ★ 27.17 | N/A |
| EPS | ★ 1.17 | N/A |
| Revenue | ★ $46,756,000.00 | $1,200,000.00 |
| Revenue This Year | N/A | $414.59 |
| Revenue Next Year | N/A | $30.15 |
| P/E Ratio | $12.26 | ★ N/A |
| Revenue Growth | ★ 8.95 | N/A |
| 52 Week Low | $11.37 | $0.39 |
| 52 Week High | $15.24 | $3.87 |
| Indicator | RMBI | RANI |
|---|---|---|
| Relative Strength Index (RSI) | 56.49 | 33.34 |
| Support Level | $13.72 | $1.20 |
| Resistance Level | $14.28 | $1.41 |
| Average True Range (ATR) | 0.31 | 0.06 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 89.71 | 18.83 |
Richmond Mutual Bancorp Inc is a United States-based banking company. Its principal business consists of attracting deposits from the general public & brokered deposits and investing those funds predominantly in loans secured by commercial and multi-family real estate, first mortgages on owner-occupied, one-to four-family residences, a variety of consumer loans, direct financing leases, and commercial and industrial loans. The company has one reportable segment which is Community Banking.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.